Biological and biomedical research offers tremendous opportunities for improving our understanding of biological mechanisms and processes and for targeting new and more effective therapies for devastating conditions. At the same time, however, this research involving recombinant DNA, infectious agents, and other potentially hazardous biologics carries inherent safety risks. Working at an appropriate biosafety containment level and with the appropriate safety precautions is essential for mitigating those risks.
As mandated by the NIH Guidelines, Baylor’s Institutional Biosafety Committee (IBC) is responsible for assessing the biosafety containment level for research involving recombinant DNA and synthetic nucleic acid molecules. The IBC also oversees research with other potentially hazardous biologics. The IBC currently oversees: